Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium

We investigated effectiveness of (1) mRNA booster vaccination versus primary vaccination only and (2) heterologous (viral vector–mRNA) versus homologous (mRNA–mRNA) prime-boost vaccination against severe outcomes of BA.1, BA.2, BA.4 or BA.5 Omicron infection (confirmed by whole genome sequencing) among hospitalized COVID-19 patients using observational data from national COVID-19 registries. In addition, it was investigated whether the difference between the heterologous and homologous prime-boost vaccination was homogenous across Omicron sub-lineages. Regression standardization (parametric g-... Mehr ...

Verfasser: Meurisse, Marjan
Catteau, Lucy
van Loenhout, Joris A. F.
Braeye, Toon
De Mot, Laurane
Serrien, Ben
Blot, Koen
Cauët, Emilie
Van Oyen, Herman
Cuypers, Lize
Robert, Annie
Van Goethem, Nina
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Verlag/Hrsg.: MDPI AG
Schlagwörter: Pharmacology (medical) / Infectious Diseases / Drug Discovery / Pharmacology / Immunology / COVID-19 vaccination / Clinical severity / SARS-CoV-2 variants
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26599347
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/2078.1/272688